Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 1:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 4,836 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Volunteers Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence Study of Nisoldipine Extended-Release Tablets, 30 mg

NCT00985660
View directory record Official record
Conditions
Healthy
Interventions
Nisoldipine Extended-release Tablets, 30 mg, Sular® Extended Release Tablets, 30 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Cellular Pharmacology of F-TAF in Dried Blood Spots

NCT02962739
View directory record Official record
Conditions
Healthy Volunteers
Interventions
emtricitabine 200 mg/tenofovir alafenamide 25mg
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 59 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and Corzide® Tablets 80 mg/5 mg

NCT00648297
View directory record Official record
Conditions
Healthy
Interventions
Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg, Corzide® Tablets 80 mg/5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 29, 2026, 1:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation

NCT00884702
View directory record Official record
Conditions
Brain Mapping
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 28 Years
Enrollment
538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

NCT03610945
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Fluconazole, Quinidine, EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 5, 2018 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

NCT02634073
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Lamivudine, Sorbitol
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

US Ovulation Inhibition Study in Obese Women

NCT00873483
View directory record Official record
Conditions
Contraception
Interventions
Ethinylestradiol/Gestodene (BAY86-5016)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
6
States / cities
Tucson, Arizona • San Diego, California • Sandy Springs, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of 2012 Bioequivalence Standards for Warfarin

NCT02574754
View directory record Official record
Conditions
Healthy
Interventions
warfarin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 29, 2026, 1:29 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers

NCT03571594
View directory record Official record
Conditions
Acromegaly
Interventions
ONO-5788, ONO-5788 Placebo, Octreotide
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CampETEC Hyperimmune Bovine Colostrum (HBC)

NCT06122870
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CampETEC HBC product, ProMilk 85, C. jejuni CG8421 Challenge strain
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

NCT06342700
View directory record Official record
Conditions
Autoimmune Disorder, Healthy Volunteers
Interventions
Rilzabrutinib crystalline form, Rilzabrutinib amorphous form
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers

NCT02030639
View directory record Official record
Conditions
Healthy
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy Volunteers

NCT03810495
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
naltrexone implant
Drug
Lead sponsor
Go Medical Industries Pty Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 29, 2026, 1:29 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of Ulonivirine (MK-8507) and Methadone in Healthy Volunteers (MK-8507-019)

NCT07595263
View directory record Official record
Conditions
Healthy
Interventions
Ulonivirine, Methadone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects

NCT01258777
View directory record Official record
Conditions
Healthy Volunteers
Interventions
400 mg golimumab or placebo, 200 mg golimumab or placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

NCT02056392
View directory record Official record
Conditions
Solid Tumours
Interventions
Selumetinib, Moxifloxacin, selumetinib placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

NCT00851734
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
voclosporin ophthalmic solution
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 29, 2026, 1:29 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Recording and Modulation of Neuronal Mechanisms During Operant Conditioning: a MEG Study

NCT01006109
View directory record Official record
Conditions
Central Nervous System
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Meloxicam Tablets 15 mg and Mobic® Tablets 15 mg

NCT00649675
View directory record Official record
Conditions
Healthy
Interventions
Meloxicam Tablets 15 mg, Mobic® Tablets 15 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 29, 2026, 1:29 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

NCT06584357
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss, Memory Disorders, Memory Impairment
Interventions
Biomarker Data Collection, MK6240
Other · Radiation
Lead sponsor
GAP Innovations, PBC
Industry
Eligibility
60 Years to 90 Years
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
22
States / cities
Atlantis, Florida • Aventura, Florida • Clermont, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Modafinil on Brain Function in Patients With Schizophrenia

NCT00057707
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Modafinil, Functional MRI, Neuropsychological Testing
Drug · Procedure
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants

NCT04640311
View directory record Official record
Conditions
Anaemia
Interventions
Daprodustat
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Anaheim, California • Overland Park, Kansas • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics Study of ATH-1020

NCT05169671
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ATH-1020, Placebo
Drug
Lead sponsor
LeonaBio
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 29, 2026, 1:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Food Effect of BLU-782 in Healthy Adults

NCT03858075
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BLU-782, Placebo, BLU-782 taken with food
Drug
Lead sponsor
Blueprint Medicines Corporation
Industry
Eligibility
19 Years to 65 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 29, 2026, 1:29 PM EDT